Carlos Cordon‐Cardo

97.5k total citations · 26 hit papers
564 papers, 68.1k citations indexed

About

Carlos Cordon‐Cardo is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Carlos Cordon‐Cardo has authored 564 papers receiving a total of 68.1k indexed citations (citations by other indexed papers that have themselves been cited), including 324 papers in Molecular Biology, 203 papers in Oncology and 118 papers in Surgery. Recurrent topics in Carlos Cordon‐Cardo's work include Cancer-related Molecular Pathways (100 papers), Bladder and Urothelial Cancer Treatments (89 papers) and Epigenetics and DNA Methylation (56 papers). Carlos Cordon‐Cardo is often cited by papers focused on Cancer-related Molecular Pathways (100 papers), Bladder and Urothelial Cancer Treatments (89 papers) and Epigenetics and DNA Methylation (56 papers). Carlos Cordon‐Cardo collaborates with scholars based in United States, Spain and Germany. Carlos Cordon‐Cardo's co-authors include Pier Paolo Pandolfi, Scott W. Lowe, Eva Hernando, Marija Drobnjak, Zvi Fuks, Howard I. Scher, Antonio Di Cristofano, M R Melamed, Adriana Haimovitz‐Friedman and Gregory J. Hannon and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Carlos Cordon‐Cardo

562 papers receiving 66.7k citations

Hit Papers

A microRNA polycistron as... 1989 2026 2001 2013 2005 2003 2007 2005 1989 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A microRNA polycistron as a potential human oncogene
    2005 2.9k citations Eva Hernando, Carlos Cordon‐Cardo et al. profile →
  2. A multigenic program mediating breast cancer metastasis to bone
    2003 2.0k citations Carlos Cordon‐Cardo et al. profile →
  3. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
    2007 1.9k citations Eva Hernando, Carlos Cordon‐Cardo et al. profile →
  4. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
    2005 1.5k citations Lloyd C. Trotman, Howard I. Scher et al. profile →
  5. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.
    1989 1.4k citations Carlos Cordon‐Cardo et al. Proceedings of the National Academy of Sciences profile →
  6. Role of the INK4a Locus in Tumor Suppression and Cell Mortality
    1996 1.3k citations Manuel Serrano, Carlos Cordon‐Cardo et al. profile →
  7. Prostate-specific membrane antigen expression in normal and malignant human tissues.
    1997 1.3k citations Carlos Cordon‐Cardo et al. PubMed profile →
  8. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53
    1998 1.2k citations Carlos Cordon‐Cardo et al. profile →
  9. Pten is essential for embryonic development and tumour suppression
    1998 1.2k citations Carlos Cordon‐Cardo, Pier Paolo Pandolfi et al. profile →
  10. Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
    2003 1.2k citations Carlos Cordon‐Cardo et al. Science profile →
  11. Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice
    2001 1.0k citations Carlos Cordon‐Cardo et al. Science profile →
  12. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.
    1990 885 citations Carlos Cordon‐Cardo et al. profile →
  13. Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach
    2006 861 citations Carlos Cordon‐Cardo et al. profile →
  14. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3
    1991 823 citations Carlos Cordon‐Cardo et al. profile →
  15. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
    2004 794 citations Carlos Cordon‐Cardo et al. profile →
  16. Mutation ofPten/Mmac1in mice causes neoplasia in multiple organ systems
    1999 786 citations Carlos Cordon‐Cardo et al. Proceedings of the National Academy of Sciences profile →
  17. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
    2001 769 citations Manel Esteller, Carlos Cordon‐Cardo et al. profile →
  18. Acid Sphingomyelinase–Deficient Human Lymphoblasts and Mice Are Defective in Radiation-Induced Apoptosis
    1996 691 citations Carlos Cordon‐Cardo et al. profile →
  19. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
    2007 674 citations Mireia Castillo-Martín, Carlos Cordon‐Cardo et al. profile →
  20. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
    2020 648 citations Carlos Cordon‐Cardo et al. Science profile →
  21. Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression
    2007 593 citations Lloyd C. Trotman, Brett S. Carver et al. profile →
  22. NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTEN
    2007 576 citations Lloyd C. Trotman, Carlos Cordon‐Cardo et al. profile →
  23. Pten Dose Dictates Cancer Progression in the Prostate
    2003 531 citations Lloyd C. Trotman, Carlos Cordon‐Cardo et al. profile →
  24. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
    1990 531 citations Carlos Cordon‐Cardo et al. PubMed profile →
  25. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    2000 521 citations David B. Agus, Howard I. Scher et al. PubMed profile →
  26. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
    2009 490 citations Brett S. Carver, Caterina Nardella et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carlos Cordon‐Cardo United States 129 41.4k 22.8k 12.8k 11.0k 7.7k 564 68.1k
Adi F. Gazdar United States 132 36.4k 0.9× 28.3k 1.2× 12.6k 1.0× 19.3k 1.7× 5.4k 0.7× 654 70.7k
John D. Minna United States 140 42.2k 1.0× 26.3k 1.2× 13.3k 1.0× 14.7k 1.3× 3.3k 0.4× 803 73.8k
Napoleone Ferrara United States 140 61.5k 1.5× 20.6k 0.9× 23.9k 1.9× 10.0k 0.9× 9.5k 1.2× 259 99.3k
Webster K. Cavenee United States 99 31.7k 0.8× 12.7k 0.6× 13.7k 1.1× 8.8k 0.8× 3.5k 0.5× 315 62.0k
Raghu Kalluri United States 120 49.4k 1.2× 21.0k 0.9× 25.3k 2.0× 9.6k 0.9× 7.2k 0.9× 321 83.3k
Mien‐Chie Hung United States 138 43.4k 1.0× 28.0k 1.2× 13.8k 1.1× 7.7k 0.7× 2.7k 0.4× 745 67.2k
Peter Carmeliet Belgium 151 53.1k 1.3× 15.0k 0.7× 27.4k 2.1× 9.1k 0.8× 9.4k 1.2× 729 100.0k
Carl‐Henrik Heldin Sweden 132 41.7k 1.0× 14.1k 0.6× 8.9k 0.7× 5.7k 0.5× 4.5k 0.6× 494 62.7k
Lance A. Liotta United States 129 34.6k 0.8× 16.9k 0.7× 16.9k 1.3× 5.2k 0.5× 3.7k 0.5× 658 62.1k
David N. Louis United States 99 27.9k 0.7× 15.3k 0.7× 17.0k 1.3× 17.5k 1.6× 4.4k 0.6× 322 75.2k

Countries citing papers authored by Carlos Cordon‐Cardo

Since Specialization
Citations

This map shows the geographic impact of Carlos Cordon‐Cardo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Cordon‐Cardo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Cordon‐Cardo more than expected).

Fields of papers citing papers by Carlos Cordon‐Cardo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Cordon‐Cardo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Cordon‐Cardo. The network helps show where Carlos Cordon‐Cardo may publish in the future.

Co-authorship network of co-authors of Carlos Cordon‐Cardo

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Cordon‐Cardo. A scholar is included among the top collaborators of Carlos Cordon‐Cardo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Cordon‐Cardo. Carlos Cordon‐Cardo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nose, Yohei, John F. Fullard, Marilyn D. Saulsbury, et al.. (2024). Extracellular vesicles, RNA sequencing, and bioinformatic analyses: Challenges, solutions, and recommendations. Journal of Extracellular Vesicles. 13(12). e70005–e70005. 43 indexed citations
2.
Pandav, Krunal, Parag Jain, Mani Menon, et al.. (2023). Applications of artificial intelligence in prostate cancer histopathology. Urologic Oncology Seminars and Original Investigations. 42(3). 37–47. 11 indexed citations
3.
Petrache, Irina, Elisabet Pujadas, Aditya Ganju, et al.. (2023). Marked elevations in lung and plasma ceramide in COVID-19 linked to microvascular injury. JCI Insight. 8(10). 14 indexed citations
4.
Fernández, Gerardo, Marcel Prastawa, Bahram Marami, et al.. (2022). Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years. Breast Cancer Research. 24(1). 93–93. 14 indexed citations
5.
Silva, Suzane Ramos da, Enguo Ju, Wen Meng, et al.. (2021). Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal Coronavirus Disease 2019. The Journal of Infectious Diseases. 223(11). 1842–1854. 29 indexed citations
6.
Chen, Ming, Jiangwen Zhang, Alice H. Berger, et al.. (2018). Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. Journal of Clinical Investigation. 129(1). 215–222. 21 indexed citations
7.
Guarnerio, Jlenia, Luisa Riccardi, Riccardo Taulli, et al.. (2015). A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells. Cancer Discovery. 5(4). 396–409. 26 indexed citations
8.
Lunardi, Andrea, Shohreh Varmeh, Ming Chen, et al.. (2015). Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery. 5(5). 550–563. 22 indexed citations
9.
Nowak, Dawid G., Hyejin Cho, Tali Herzka, et al.. (2015). MYC Drives Pten/Trp53 -Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discovery. 5(6). 636–651. 64 indexed citations
10.
Cho, Hyejin, Tali Herzka, Zheng Wu, et al.. (2014). RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten -Mutant Metastasis. Cancer Discovery. 4(3). 318–333. 68 indexed citations
11.
Samon, Jeremy B., Mireia Castillo-Martín, Michael Hadler, et al.. (2012). Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics. 11(7). 1565–1575. 86 indexed citations
12.
Smith, Blair H., Lawrence S. Gazda, Daniel M. Levine, et al.. (2011). Three-Dimensional Culture of Mouse Renal Carcinoma Cells in Agarose Macrobeads Selects for a Subpopulation of Cells with Cancer Stem Cell or Cancer Progenitor Properties. Cancer Research. 71(3). 716–724. 43 indexed citations
13.
Seager, Catherine M., Anna M. Puzio‐Kuter, Trushar Patel, et al.. (2009). Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer. Cancer Prevention Research. 2(12). 1008–1014. 61 indexed citations
14.
Cebrián, Virginia, Virginia López, Esteban Orenes‐Piñero, et al.. (2008). Identification of PMF1 Methylation in Association with Bladder Cancer Progression. Clinical Cancer Research. 14(24). 8236–8243. 29 indexed citations
15.
Becher, Oren J., Dolores Hambardzumyan, Elena I. Fomchenko, et al.. (2008). Gli Activity Correlates with Tumor Grade in Platelet-Derived Growth Factor–Induced Gliomas. Cancer Research. 68(7). 2241–2249. 151 indexed citations
16.
Feng, Zhaohui, Wenwei Hu, Angelika K. Teresky, et al.. (2007). Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations. Proceedings of the National Academy of Sciences. 104(42). 16633–16638. 208 indexed citations
17.
González, Susana, Manuel M. Pérez‐Pérez, Eva Hernando, Manuel Serrano, & Carlos Cordon‐Cardo. (2005). p73β-Mediated Apoptosis Requires p57kip2 Induction and IEX-1 Inhibition. Cancer Research. 65(6). 2186–2192. 39 indexed citations
18.
Ruggero, Davide, Silvia Grisendi, Francesco Piazza, et al.. (2003). Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification. Science. 299(5604). 259–262. 345 indexed citations
19.
Hoos, Axel, Marshall Urist, Alexander Stojadinovic, et al.. (2001). Validation of Tissue Microarrays for Immunohistochemical Profiling of Cancer Specimens Using the Example of Human Fibroblastic Tumors. American Journal Of Pathology. 158(4). 1245–1251. 331 indexed citations
20.
Agus, David B., Howard I. Scher, Brian Higgins, et al.. (1999). Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.. PubMed. 59(19). 4761–4. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adi F. Gazdar Breakdown of academic impact, for papers by John D. Minna Breakdown of academic impact, for papers by Napoleone Ferrara Breakdown of academic impact, for papers by Webster K. Cavenee Breakdown of academic impact, for papers by Raghu Kalluri Breakdown of academic impact, for papers by Mien‐Chie Hung Breakdown of academic impact, for papers by Peter Carmeliet Breakdown of academic impact, for papers by Carl‐Henrik Heldin Breakdown of academic impact, for papers by Lance A. Liotta Breakdown of academic impact, for papers by David N. Louis
Rankless by CCL
2026